Member Info for rivaldo

The overnight summary from Investors' Champion on the trading update FYI:

"Belvoir: trading ahead

Belvoir Group (LON:BLV), which calls itself the UK's largest property franchise, confirmed that trading in the ten months to the end of October 2020 was ahead of its pre-Covid expectations with both its property and the financial services divisions achieving year on year growth in gross profit of 10% and 11% respectively.

With costs under control pre-tax profits for the year to 31 December are now anticipated to be comfortably ahead of management's expectations.

Cash has also continued to flow with net debt currently down to £4.3m (31 December 2019: £6.9m), this after having deployed £2.0m of cash in January to acquire the Lovelle network and deferred payment of £0.5m VAT.

Resilient trading means they are able to reimburse staff in full for the salaries sacrificed earlier in the year and also repay all government support monies

A catch-up dividend of 1.3p is also being paid bringing the total reinstated 2019 dividend to 3.3p per share, equivalent to a yield of 2.1%."

FinnCap have now lifted their target price to 125p following today's latest earnings-enhancing acquisition.

They pencil in a 14% EPS uplift to next years numbers, with revenue forecast to move to £35m and an adj pre-tax profit of £5.7m.

Today's RNS confirms big demand for the shares - unsurprising given the excellent news.

So that news is terrific - but surely CAPD could have used this opportunity to place the final tranche of CB's shares (and also any from R&M, who were selling recently) rather than issuing further stock to meet the evidently huge demand for those shares given the oversubscription?

Onwards and upwards from here anyway given the excellent prospects and outlook.

Hopefully this is all designed such that the upcoming year end trading statement will reward the new institutional shareholders for their eagerness to subscribe.

Very good news this morning for RNWH's cash flows and Balance Sheet - and it would seem that one more £4m payment to AMCO's scheme will increase cashflow permanently by close to £5m a year. :

Https://uk.advfn.com/stock-market/london/renew-RNWH/share-news/Renew-Holdings-PLC-Buy-in-of-Pension-Scheme-Liabil/83818869

"Sean Wyndham-Quin, Renew's CFO, commented:

"We are very pleased that the Trustee of the Lovell Scheme has completed the recent buy-in with a specialist insurer. This transaction significantly de-risks the Group's balance sheet, further reduces the Group's pension exposure risks and improves the Group's cashflow in the medium term. We are now focused on trying to fully buy-in our liabilities with the Amco Scheme to further reduce the Group's pension exposure in line with our strategy."

Another very good acquisition - and a timely one given the increasing demand for Monmouth's products due to COVID which will continue for some time yet.

Immediately earnings-enhancing - and the scale of the upside can be seen from the earn-out provisions, which are only payable based on Monmouth achieving adjusted EBIT for the current year in excess of £1.9m. This against a likely £5.9m total consideration.

Agreed Scoobydoo321. The InvestorMeet presentation specifically mentioned that SBI were talking to Pfizer and others from memory about storage for vaccines from memory, with SBI being one of the few UK companies capable of doing this.

With Pfizer's vaccine about to start distribution imminently, perhaps there might be news soon. Let's hope so!

I wonder whether WIN's refrigerated vehicle fleet will have a role to play in the huge task of distributing the Pfizer vaccine which was approved today?

Https://www.wincanton.co.uk/markets/grocery/

Picked a few of these up today after the excellent update. Have seen them present a couple of times in the past and always struck me as knowledgeable, able and honest. A happy combination!

Finncap have reiterated their 233p valuation, and have increased this year's forecast to 15.2p EPS.

They also note that 2020 dividends will total 10.5p per share.

Buying coming in at 534p and 540p now....

Good to se a tick up after a £5k buy. Here's a reinstatement of where REAT are at the current 1.05p share price.

REAT now have a £3.2m EV (£4.99m m/cap less £1.8m cash). For the current year, a similar upswing to the last year to 30/9/20 would see PBT at well over £500k - an ex-cash P/E of only 6.4 and an extraordinarily cheap PEG.

Even at a much reduced growth rate, with PBT of say £350k PBT that P/E would still be only 9.1.

There's also the likelihood that REAT will make an earnings-enhancing acquisition from the cash pile to additionally jump-start earnings.

Furthermore, in the year just ended REAT made a considerable investment in additional staff and overheads to achieve faster growth. Not only will this have dampened the numbers for last year, but it will benefit this year's numbers as the the new staff are now up to speed and more productive.

The PEG (even based on the higher P/E of 9.1) falls to a mere 0.1 or so. As we know, any PEG below 1 is deemed to be good value. REAT's PEG is therefore an out and out bargain on this basis.

Worth remembering that the £1.8m cash now represents over 36% of the current m/cap.

Fantastic news - an enormous new contract at Sukari "of US$235 - 260 million over a four-year period commencing 1 January 2021, representing the largest award of new business in the Company's history".

Also, a £22m placing at 58p to part-fund the necessary cap ex. This could have been at 75p-80p at minimum if not for Craig Burton, whose selling of his founder stake has held the share price down.

Good to see all the directors putting more money in. Hopefully this huge contract win will see the share price rally nicely given the terrific prospects for CAPD from both the exciting business already in place and now this extra turbo boost.

News of PrimeStore devices being used for Concepta's DNA testing service and its COVID-19 swab kit:

Https://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/Concepta-PLC-Genomic-testing-service-launch-and-Ch/83807908

with buying coming in at 518p now.

https://www.fool.co.uk/investing/2020/12/01/top-british-stocks-for-december-2020/

That's good company for MWE to be keeping considering all the other tipped companies are absolutely huge! Let's hope MWE's m/cap is £500m one day, which appears to be about the lowest m/cap of all the rest....

Here's the summary of Cenkos' upgrade to Buy:

"Firing Up

The Group’s cash generation and profitability remained robust in H1/21A despite the onset of COVID-19. This enabled the Group to pay down a further £8.2m of term loan principal, resulting in net debt declining 44.6% to £34.9m. In light of improving visibility in industrial electricity demand we release prudent FY21E and FY22E forecasts. We believe OPG is undervalued, trading at a c50% discount to its peer Group. We move our recommendation from Under Review to Buy.

?H1/21A Financial Performance.

The Group’s profitability remained robust despite the onset of COVID materially impacting trading in H1/21A. Government enforced lockdowns caused a reduction in industrial electricity demand. In response OPG reduced plant load factors and in turn generation (H1/21A 831m kWh vs H1/20A 1,440m kWh). This reduction combined with a 1% decline in tariff to 5.60Rs/kWh caused revenue to decline 54% to £36.1m. Adjusted EBITDA, including a one-off £9.6m collection of accrued contractual claims, increased 16% to £19.4m. This in conjunction with lower coal and freight costs supported the Group’s margin profile. As a result, EPS increased 48.2% to 2.9p per share.

?Deleveraging Strategy.

OPG has continued to deliver its deleveraging strategy, paying down a further £8.2m of term loan principal. The Group also refinanced a portion of its debt with non-convertible debentures (NCD), pushing repayments out to June 2022. As a result, net debt has reduced by 44.6% to £34.9m, comprised of £21.1m NCDs, £21.8m term loans, £1.4m working capital loans and £9.4m in cash. We expect the Group to fully repay its term loans by Q2/24, increasing free cash flow to equity and, in time, enabling cash distribution to shareholders via dividends.

?Forecast Re-initiation.

We release prudent FY21E and FY22E forecasts in light of ongoing macroeconomic aberrations in India. We expect revenue of £93.6m in FY21E and £112.2m in FY22E. Importantly, due to a one-off £9.6m collection of accrued contractual claims, EBITDA increases 6% YoY to £33.0m and in line with lower tariffsand marginally higher input costs, declines to £24.7m in FY22E. As a result, we expect adjusted diluted EPS of 3.4p and 1.8p in FY21E and FY22E, respectively.

?Investment Case.

We believe OPG trades below its fair value. The market continues to undervalue its improved capital structure, its highly profitable cash generative business model and the long-term structural dynamics for sustainable growth in the power generation sector. We believe the Group offers value to investors whilst trading at a c50% discount to its peer group (please see valuation section on page 7). We move our recommendation from Under Review to Buy"

New eight minute interview with the CEO - all very bullish, particularly the early success of the new monetisation product which also includes cybersecurity (including SSL certificates):

Https://www.***************************/centralnic-group-see-substantial-growth-in-demand-for-services-interview/412942946

Buying coming in at 262p now...

The recovery continues.....

Cenkos have upgraded to Buy - they say that applying peer group multiples gives values of at minimum 40.7p up to 67.9p.....comapted to the current 13.25p share price.

Very encouraging numbers and outlook today. Net debt is reducing VERY fast now, particularly with the post balance sheet 9m debtor recovery cash inflow to be included.

Substantial upside here with the strategy now really starting to pay off - and this despite the pandemic.

There are some interesting points in Cenkos' long update note from a few days ago:

- they've calculated a pro forma forecast for the coming year ssuming the three mooted acquisitions complete reasonably quickly. This produces 6.75p EPS and £11.4m EBITDA, up 62% on the prior forecast
- imo that would justify a share price somewhere between 130p-150p
- VLG can almost double the manufacturing capacity in Italy from current capacity of 55m units to 100m units for only £7m total investment, with an initial £3m allowing 75m units production
- Pharmasource grew 40% in H1'20, and that was before synergies which should deliver further growth in 2021